- Home
- Solutions
- By Diseases
- Ocular Neoplastic Diseases
- Conjunctival Squamous Cell Carcinoma
A uniquely serious malignancy of the eye, Squamous Cell Carcinoma of the Conjunctiva is one of the rarest types of OSSN. Protheragen prides itself on offering customized services to address the specific challenges of conjunctival squamous cell carcinoma diagnostics and therapeutics development.
Conjunctival Squamous Cell Carcinoma represents a relatively uncommon tumour with an aggressive behaviour that originates from squamous neoplasms of the conjunctiva, which is the delicate membrane that covers the anterior portion of the eyeball and lines the inside of the eyelids. It is the fourth most common ocular surface malignancy and, if not managed in a timely fashion, can result in considerable morbidity including blindness and facial distortion. Strong associations with conjunctival squamous cell carcinoma include ultraviolet (UV) radiation, HPV and immunosuppression.
Fig.1 Histopathology images of scleral biopsy. (Uner O. E., et al., 2024)Histopathological Examination
The most effective approach to making a diagnosis for conjunctival squamous cell carcinoma remains histopathology. This entails the microscopic analysis of keratinised tissue biopsies containing dysplastic squamous cells with identifiable invasive growth patterns. Immunohistochemical analysis using p53 and Ki-67 enhances the accuracy of the
Molecular Diagnostics
Different techniques such as polymerase chain reaction (PCR) and next generation sequencing (NGS) have been developed to trace the genetic mutations like TP53 and even HPV DNA. The analysis of circulating tumour DNA (ctDNA) through liquid biopsy is an emerging non-invasive diagnostic method.
Biomarker Analysis
Research into biomarkers such as matrix metalloproteinases (MMPs) and vascular endothelial growth factor (VEGF) has shown promise in predicting tumor behavior and guiding therapeutic decisions.
In regard to services like diagnostics and therapeutics for conjunctival squamous cell carcinoma, Protheragen is a leading company. We undertake our work from the earliest stages of research to the most advanced stages of preclinical development using state-of-the-art technologies and approaches. Every project we take on is bespoke, thus ensuring the powerful combination of science-driven rigor and innovation.
Protheragen specializes in conducting rigorous preclinical studies to validate the efficacy and safety of new therapeutic agents, providing critical data to support clinical advancement. If you are interested in our services, please feel free to contact us.
References
Copyright © Protheragen. All rights reserved.